Albert David appoints Amit Mahla as Whole-time Director and CEO for 5 years

Ceo Appointed ExternalManagement Changes View source PDF Explain this filing

ALBERTDAVD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.6%Reaction day

₹710.50

prior close

₹725.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.8%-0.2% vs market

Pharmaceuticals peers, median of 162sector+0.5%+0.1% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-0.7

15m

-0.7

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.6+0.8-0.2+0.5+0.1

Next day

+0.5+0.1+0.4+1.5-0.9

+0.2+0.0+0.2+1.1-0.9

-0.7-0.6-0.2+0.8-1.6

-0.4-0.9+0.5+1.0-1.3

-1.8+0.2-1.9+2.7-4.5

+0.9+1.2-0.3+2.3-1.4

15d

-2.2+0.7-2.9+4.3-6.5

-3.3-0.4-2.9+2.6-5.9

+25.5+5.2+20.4+2.8+22.7

+19.6+5.4+14.2+7.1+12.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Albert David's Board has appointed Mr. Amit Mahla (DIN: 11767012) as Additional Director and Whole-time Director and CEO for 5 years from June 19, 2026 to June 18, 2031. He was already serving as CEO since May 12, 2026. Mr. Mahla, aged 52, has over 28 years of pharma experience across Cipla, Emcure, Glenmark, Alembic, Sun Pharma, and JB Pharma. He is not related to any existing director or KMP and his appointment is subject to shareholder approval at the 87th AGM.

Likely market impact

Formalizes CEO role with a seasoned pharma industry veteran. Appointment needs shareholder nod at 87th AGM; remuneration fixed till March 31, 2027.